Literature DB >> 20820782

Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity.

Lei Chen1, Shi-zhong Zheng, Zhi-guang Sun, Ai-yun Wang, Chen-hu Huang, Neville A Punchard, Shi-le Huang, Xiang Gao, Yin Lu.   

Abstract

PURPOSE: Cryptotanshinone is a major active component of Salvia miltiorrhiza, which is often used as Chinese herbal medicine in cancer therapy. Here, we systematically assessed the anti-tumor effect of Cryptotanshinone on two melanoma cell lines with low/high-metastatic capacity (B16/B16BL6).
METHODS: MTT and LDH assays were used to evaluate cell growth and cytotoxicity. We assessed the effect of Cryptotanshinone on cell apoptosis or proliferation by Annexin V, TUNEL or BrdU assay. Cell cycle distribution was detected by flow cytometry. The integrity of cell cycle checkpoints was determined by mutational analyses of B-RAF and N-RAS, and the expression of cell cycle-associated proteins by western blotting.
RESULTS: Treatment with Cryptotanshinone had no obvious effect on cell apoptosis but significantly inhibited cell proliferation. Cryptotanshinone slightly increased the expression of p53, Chk1, and Chk2 in both B16 and B16BL6. Interestingly, Cryptotanshinone induced G1 arrest with a concomitant increase in p21 expression in B16BL6 cells. However, in B16 cells, Cryptotanshinone induced the G2/M arrest through its induction of Cdc25c. Regulation of Cyclin A1, Cyclin B1 and Cdk1/cdc2 expression might contribute to the different cell cycle patterns in B16 and B16BL6 after Cryptotanshinone treatment.
CONCLUSIONS: Cryptotanshinone could have diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity. This property might offer an opportunity to study underlying mechanisms for the different antitumor effects of administered Cryptotanshinone in B16 and B16BL6 cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20820782      PMCID: PMC3032829          DOI: 10.1007/s00280-010-1440-8

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

1.  Inhibition of mast cell degranulation by tanshinones from the roots of Salvia miltiorrhiza.

Authors:  S Y Ryu; M H Oak; K M Kim
Journal:  Planta Med       Date:  1999-10       Impact factor: 3.352

2.  Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1.

Authors:  F Casagrande; J M Darbon
Journal:  Biochem Pharmacol       Date:  2001-05-15       Impact factor: 5.858

3.  Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza.

Authors:  B Y Kang; S W Chung; S H Kim; S Y Ryu; T S Kim
Journal:  Immunopharmacology       Date:  2000-09

Review 4.  Malignant melanoma: prevention, early detection, and treatment in the 21st century.

Authors:  D S Rigel; J A Carucci
Journal:  CA Cancer J Clin       Date:  2000 Jul-Aug       Impact factor: 508.702

5.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

Authors:  Q Liu; S Guntuku; X S Cui; S Matsuoka; D Cortez; K Tamai; G Luo; S Carattini-Rivera; F DeMayo; A Bradley; L A Donehower; S J Elledge
Journal:  Genes Dev       Date:  2000-06-15       Impact factor: 11.361

6.  Treatment of chronic liver diseases with traditional Chinese medicine.

Authors:  B E Wang
Journal:  J Gastroenterol Hepatol       Date:  2000-05       Impact factor: 4.029

Review 7.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

8.  Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.

Authors:  Yi-He Ling; Jian-Dong Jiang; James F Holland; Roman Perez-Soler
Journal:  Mol Pharmacol       Date:  2002-09       Impact factor: 4.436

9.  NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest.

Authors:  I Manni; G Mazzaro; A Gurtner; R Mantovani; U Haugwitz; K Krause; K Engeland; A Sacchi; S Soddu; G Piaggio
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

Review 10.  Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways.

Authors:  N Rhind; P Russell
Journal:  J Cell Sci       Date:  2000-11       Impact factor: 5.285

View more
  18 in total

1.  Cryptotanshinone inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3/ERK and small GTPase pathways.

Authors:  Yan Luo; Wenxing Chen; Hongyu Zhou; Lei Liu; Tao Shen; J Steven Alexander; Shizhong Zheng; Yin Lu; Shile Huang
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

Review 2.  Molecular evidence of cryptotanshinone for treatment and prevention of human cancer.

Authors:  Wenxing Chen; Yin Lu; Guangying Chen; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

3.  Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E.

Authors:  Yuqing Ge; Rubin Cheng; Yuhong Zhou; Jianping Shen; Laijun Peng; Xiaofeng Xu; Qun Dai; Pei Liu; Haibing Wang; Xiaoqiong Ma; Jia Jia; Zhe Chen
Journal:  Mol Cell Biochem       Date:  2012-05-22       Impact factor: 3.396

4.  Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro.

Authors:  Weidong Li; Shakir M Saud; Matthew R Young; Nancy H Colburn; Baojin Hua
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

5.  Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling.

Authors:  Shanhu Li; Hongtao Wang; Liu Hong; Wei Liu; Fang Huang; Jian Wang; Peng Wang; Xiaoqing Zhang; Jianguang Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 6.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

7.  Isocryptotanshinone Induced Apoptosis and Activated MAPK Signaling in Human Breast Cancer MCF-7 Cells.

Authors:  Xuenong Zhang; Weiwei Luo; Wenwen Zhao; Jinjian Lu; Xiuping Chen
Journal:  J Breast Cancer       Date:  2015-06-26       Impact factor: 3.588

8.  A promising "TRAIL" of tanshinones for cancer therapy.

Authors:  Tsing-Fen Ho; Chia-Che Chang
Journal:  Biomedicine (Taipei)       Date:  2015-11-28

Review 9.  Tanshinones: sources, pharmacokinetics and anti-cancer activities.

Authors:  Yong Zhang; Peixin Jiang; Min Ye; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Int J Mol Sci       Date:  2012-10-22       Impact factor: 5.923

10.  Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy.

Authors:  Claire Viallard; Jean-Michel Chezal; Florence Mishellany; Isabelle Ranchon-Cole; Bruno Pereira; Aurélie Herbette; Sophie Besse; Zied Boudhraa; Nathalie Jacquemot; Anne Cayre; Elisabeth Miot-Noirault; Jian-Sheng Sun; Marie Dutreix; Françoise Degoul
Journal:  Oncotarget       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.